The Bradley Hospital observational study of 81 adolescents aged 14-17 used MRI tissue-iron levels as a noninvasive proxy for dopamine neurophysiology and found lower values in subcortical reward regions among repeated cannabis users, with potency amplifying the association. This cross-sectional design cannot establish whether cannabis exposure drives the differences or whether pre-existing reward-circuit variations predispose teens to heavier use. Prior longitudinal work, such as the 2022 IMAGEN cohort analysis in JAMA Psychiatry (n=1,200+), similarly linked early cannabis onset to blunted ventral-striatal reward responses years later, yet also documented baseline impulsivity predicting uptake, underscoring bidirectional risk. A 2024 systematic review in Neuropsychopharmacology (covering 14 studies) noted consistent dopamine-related PET and MRI alterations in adult chronic users but highlighted the scarcity of adolescent data and frequent failure to control for tobacco co-use or socioeconomic status. The current paper therefore adds a novel iron biomarker but inherits the same interpretive limits: small sample, single time point, and no reported conflicts of interest or preregistration. Parents interpreting these findings as proof of permanent pathway damage should weigh them against evidence that some reward-circuit changes appear partially reversible with sustained abstinence in young adults, while recognizing that any disruption during the adolescent dopamine surge warrants caution regardless of ultimate causality.